Dasatinib, sold under the brand name Sprycel, is a chemotherapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).

Market Analysis and Insights: Global and Japan Sprycel Market
This report focuses on global and Japan Sprycel market.
In 2020, the global Sprycel market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Sprycel market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Sprycel Scope and Market Size
Sprycel market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Sprycel market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Sprycel market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
20mg
50mg
70mg

Segment by Application
CML
ALL

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Bristol-Myers Squibb
LUCIUS Pharma